

Human Keratin Hydrogel Matrices are Degradation Resistant and Maintain Efficacy in Chronic Wound Models

Allison N. Ramey-Ward PhD, Kesia Smith BS, Howard P. Walthall, Thomas H. Barrows PhD | ProgenaCare Global, LLC, Marietta, GA, USA 30033


INTRODUCTION

When inflammation becomes dysregulated in the wound healing process, excess proteases can accumulate that may slow wound healing¹, and significant research has been conducted to characterize the levels of human neutrophil elastase (HNE) and matrix metalloproteases (MMPs) that contribute to wound chronicity².

Many biomaterial advanced wound care products are based in extracellular matrix proteins and are susceptible to protease degradation³. Some such products are reapplied weekly or even more frequently to ensure they maintain efficacy.

Keratin has been shown to be both resistant to enzyme degradation⁴ and suppressive to enzyme activity⁵. In this work, we tested if the previously demonstrated wound healing efficacy a human keratin hydrogel matrix (HKHM) if applied for multiple weeks at a time. Additionally, we investigated the ability of HKHM to reduce the activity of HNE and MMP-9 to better understand its role in wound healing.


METHODS OTHER DESCRIPTION OF THE PROPERTY OF




SIGNIFICANCE

Skin substitute advanced wound care products are often reapplied at weekly intervals. If such a product can maintain efficacy for longer, fewer applications would be required to achieve the same healing outcomes. Given the high cost of wound care, this could have a significant impact not only on patient quality of life but also their healthcare costs.


RESULTS




The human keratin hydrogel matrix (HKHM) does not degrade in an artificial wound fluid⁶ that mimics the biochemical composition of wound exudate. Increase in sample weight may suggest absorption or adsorption of wound fluid components



Results of the *in vivo* treatment of db/db mouse wounds with standard of care, HKHM reapplied weekly, and HKHM reapplied every two weeks. a) Average wound size measured at two-week intervals. b) Percentage of wounds healed at each wound measurement interval. c) Two-way ANOVA results showing the effect of each treatment on average wound size. d) Representative photo of a mouse at 4 weeks after wounding, when 100% of biweekly HKHM-treated wounds were healed.





HKHM suppressed the activity of MMP-9 in vitro, to the level of the MMP inhibitor NNGH. HNE activity was not significantly changed. *p<0.05, **p<0.01, ***p<0.001 for n=3 samples by Brown-Forsyth ANOVA with Dunnett's multiple comparisons.

DISCUSSION

Many skin substitute products are hypothesized to work by interaction with wound enzymes. Here, we show that HKHM can suppress MMP-9 activity *in vitro*, but has little efficacy against elastase. The role of neutrophils and their products in wound healing is debated, with both excessive and reduced levels delaying wound healing⁷. Future study is needed to clarify how keratin and neutrophils interact in wound healing.

We also demonstrate that leaving HKHM in place on wounds for up to two weeks does not impact its healing efficacy in a chronic wound model. This is likely due to the physical nature of HKHM's proposed action in the wound, relying on contact with wound bed cells rather than releasing materials or degrading quickly into the wound bed.



REFERENCES

- 1. McCarty SM & Percival SL. *Adv Wound Care 2013;* 2(8): p 438-447
- 2. Serena TE et al. *Wound Rep Regen 2016;* 24: p 589-595
- 3. Matthew-Steiner SS et al. *Bioeng 2021;* 8(5): 63
- 4. Lin X et al. *Appl Environ Microbiol 1992;* 58(10): p 3271-3275
- 5. Jin H-S et al. *J Agric Food Chem 2018;* 66(48): p 12719-12729
- 6. Lutz JB et al. *Ost Wound Man 2011;* 57(8): p 28-36
- 7. Wilgus TA et al. *Adv Wound Care 2013*; 2(7): p 379-3888. Some figures created with *Biorender.com*